INC Research to Present at Upcoming Nasdaq Investor Conference

RALEIGH, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq: INCR), a leading global Phase I to Phase IV contract research organization, today announced that Chief Executive  Officer Alistair Macdonald is scheduled to present at the Nasdaq 35th Investor Program in London, UK. Mr. Macdonald’s  presentation is scheduled for Tuesday, Nov. 29, 2016, at 10:30 a.m. GMT.

Links to INC Research’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.

About INC ResearchINC Research (Nasdaq: INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.

Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
Phone: +1 (919) 745-2745
Email: [email protected]

Press/Media Contact:
Lori Dorer
Senior Director, Corporate Communications
Phone: +1 (919) 745-2890
Email: [email protected]

You May Also Be Interested In

• InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
• InterCure raises NIS 22M in private placement at a share premium
• dynaCERT Announces Closing of $5M Non-Brokered Private Placement